William Blair analyst Brandon Vazquez has maintained their bullish stance on PRCT stock, giving a Buy rating yesterday.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Brandon Vazquez has given his Buy rating due to a combination of factors including the company’s performance in the third quarter and future growth prospects. Despite a 6% drop in share prices after the market, third-quarter sales exceeded expectations by 3%. The decline in share price is attributed to lower-than-anticipated handpiece utilization and revised guidance for 2025, which is seen as a temporary issue related to the ramp-up of Hydros systems.
New CEO Larry Wood’s strategic vision and improved commercial onboarding strategies are expected to enhance utilization rates starting in the fourth quarter. The Hydros systems are generally more utilized than legacy systems, indicating no inherent issues with the product itself. Wood’s initial guidance for 2026 aligns closely with market expectations, removing uncertainty and setting the stage for future execution. With shares trading at four times the 2026 sales forecast, Vazquez maintains an Outperform rating, anticipating better execution in upcoming quarters.
Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., PROCEPT BioRobotics, and Align Tech. According to TipRanks, Vazquez has an average return of -0.8% and a 42.47% success rate on recommended stocks.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $50.00 price target.